March 2026
Statin side effects listed in product labels overstated, finds meta-analysis
By Rebecca Jenkins
Most of the side effects listed in the product labels for statins are not caused by the medication, a large meta-analysis finds.
Statin product labels listed multiple potential adverse effects based mainly on nonrandomised and nonblinded studies, which might be subject to bias, UK and Australian researchers wrote in The Lancet.
For this study, researchers identified 66 potential side effects that were listed in the package leaflets for five statins, other than the established risks of myopathy, muscle pain and an increase in new diagnoses of diabetes. These effects included cognitive impairment, depression, sleep disturbance, peripheral neuropathy, headache, erectile dysfunction and nausea.
Analysing individual participant-level data from 19 double-blind randomised studies of statin therapy involving 123,940 people, they found 62 of the 66 side effects occurred as often among people taking statins as among controls.
Four adverse effects were found to be slightly more common among people taking statins: abnormal liver transaminases, other liver function test abnormalities, urinary composition alteration and oedema.
The researchers noted there was no increased risk of serious liver disease, such as liver failure or hepatitis.
They also analysed data from 30,724 participants who had taken part in trials comparing more intensive with less intensive statin therapy. Here they also found significant excesses for abnormal liver transaminases and other liver function test abnormalities, supporting a dose-dependent effect. However, in this analysis there was no link with urinary composition changes or oedema.
In light of the findings, the researchers called for a revision of labelling and other sources of health information to allow doctors and patients to make ‘appropriately informed decisions regarding statin therapy’.
Professor Garry Jennings AO, Chief Medical Adviser at the National Heart Foundation of Australia, welcomed the study, noting it was the largest and most rigorous analysis to date, aggregating data from large, randomised, placebo-controlled statin trials conducted under tightly controlled conditions.
‘By directly comparing statin and placebo groups, this analysis allows us to distinguish symptoms that occur coincidentally from those that are genuinely attributable to the drug,’ Professor Jennings told Medicine Today.
‘The findings show that the vast majority of these symptoms occur at similar rates in people taking placebo, reinforcing that true statin intolerance is uncommon.’
Acknowledging the time pressure on GPs when counselling patients, Professor Jennings said the long list of effects in product labels made it impractical – and often unhelpful – to go through each one in detail.
‘A more effective approach is to focus on the overall balance of benefit and risk. Statins substantially reduce the risk of heart attack and stroke and are prescribed based on strong evidence and national guidelines.’
Professor Jennings said patients should be encouraged not to stop statins without discussing symptoms with their care team, given most side effects were manageable, and many were not caused by the medication itself.
‘Where symptoms do occur, they can usually be addressed through dose adjustment, brief interruption or trial of an alternative statin,’ he added.